Daraxonrasib doubles pancreatic cancer survival
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Daraxonrasib nearly doubled overall survival time for pancreatic cancer patients in a clinical trial.
- Revolution Medicines is offering daraxonrasib through an expanded access program for critically ill patients outside of clinical studies.
- Amy Johnston, a 35‑year‑old pancreatic cancer patient, is awaiting trial results and may seek daraxonrasib via the expanded access program if her current treatment fails.
- Patients are anxious that Revolution Medicines, as a small company, may not be able to produce enough daraxonrasib to meet demand.
- Daraxonrasib is expected to be approved as a second‑line therapy for pancreatic cancer.
Why it matters: Pancreatic cancer patients stand to gain longer survival from daraxonrasib, yet the drug’s limited production by Revolution Medicines could leave many without access, intensifying competition for scarce doses.
